Drug Trial Radar · NCT04567329
Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)
Last checked: Nov 20, 2026Latest source record: Aug 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
620
Actual
Start
Nov 18, 2020
Primary completion
Aug 30, 2021
Study completion Aug 30, 2021
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Sep 28, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objectives of this trial are to assess the efficacy, safety, and tolerability of NOV03 ophthalmic solution in comparison to a saline control for the treatment of the signs and symptoms of Dry Eye Disease (DED) associated with Meibomian Gland Dysfunction (MGD).
Conditions
- Dry Eye Disease
Interventions
NOV03Drug
100% perfluorohexyloctane
Saline SolutionDrug
0.6% sodium chloride solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Total Corneal Fluorescein Staining Score (NEI Scale) in the Study Eye at Day 57Time frame: Assessed at Day 57
- Change From Baseline in Dryness Score (Visual Analogue Scale [VAS] Severity of Dryness) at Day 57Time frame: Assessed at Day 57
Locations
35 sites in 1 country. Site status is shown where the registry gives one.
Bausch Site 206
Phoenix, Arizona
Bausch Site 202
Garden Grove, California
Bausch Site 221
Hemet, California
Bausch Site 214
Inglewood, California
Bausch Site 226
Murrieta, California
Bausch Site 213
Santa Ana, California
Bausch site 236
Westminster, California
Bausch site 225
Grand Junction, Colorado
Bausch Site 211
Delray Beach, Florida
Bausch Site 204
Morrow, Georgia
Bausch Site 209
Chicago, Illinois
Bausch site 218
Hoffman Estates, Illinois
Bausch Site 230
Overland Park, Kansas
Bausch Site 207
Louisville, Kentucky
Bausch Site 228
Havre de Grace, Maryland
Bausch Site 231
Bloomington, Minnesota
Bausch Site 229
St Louis, Missouri
Bausch Site 224
St Louis, Missouri
Bausch Site 217
Washington, Missouri
Bausch Site 208
Rochester, New York
Bausch Site 210
Asheville, North Carolina
Bausch site 233
High Point, North Carolina
Bausch site 232
Southern Pines, North Carolina
Bausch Site 201
Cincinnati, Ohio
Bausch Site 216
Cleveland, Ohio
Bausch Site 223
Columbus, Ohio
Bausch Site 215
Nashville, Tennessee
Bausch site 235
Austin, Texas
Bausch Site 219
Cedar Park, Texas
Bausch Site 212
League City, Texas
Bausch site 234
San Antonio, Texas
Bausch Site 222
San Antonio, Texas
Bausch Site 203
San Antonio, Texas
Bausch Site 220
Norfolk, Virginia
Bausch Site 227
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.